Chester County News and Community Website
BERWYN, PA — AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide stakeholders with comprehensive insights into current and upcoming specialty and rare …
AscellaHealth Launches Specialty & Rare Pipeline Digest to Guide Pharmaceutical Stakeholders Read More BERWYN, PA — AscellaHealth has unveiled its Specialty & Rare Pipeline Digest™, a comprehensive digital resource aimed at providing critical information on specialty and rare disease drug launches, biosimilars, and cell …
AscellaHealth Introduces Specialty & Rare Pipeline Digest to Advance Healthcare Insights Read More BERWYN, PA — AscellaHealth has unveiled its latest edition of the Specialty & Rare Pipeline Digest™, a vital digital resource that tracks developments in specialty and rare disease medications, including …
AscellaHealth Highlights Market Trends with Specialty & Rare Pipeline Digest Read More
WASHINGTON, D.C. — The Food and Drug Administration announced plans to create a Rare Disease Innovation Hub to accelerate the development of treatments for rare diseases. This initiative, detailed in …
FDA Launches Rare Disease Innovation Hub to Boost Treatment Development Read More
HARRISBURG, PA — Community pharmacists across Pennsylvania are applauding the recent signing of House Bill 1993 by Governor Josh Shapiro. This new law aims to overhaul how pharmacy benefit managers …
Pennsylvania Community Pharmacists Cheer New Law Reforming Pharmacy Benefit Managers Read More BERWYN, PA — AscellaHealth has unveiled its latest Specialty & Rare Pipeline Digest™ for the second quarter of 2024. This quarterly publication is known for its extensive coverage of new, …
AscellaHealth Releases Quarterly Specialty & Rare Pipeline Digest Read More BERWYN, PA — AscellaHealth has released its latest edition of the Specialty & Rare Pipeline Digest™. This quarterly digital publication stands as the industry’s most detailed resource on imminent specialty …
AscellaHealth Unveils Quarter’s Insights on Specialty and Rare Disease Drug Developments Read More